Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.88

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received a consensus rating of “Moderate Buy” from the seventeen research firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $55.38.

Several equities research analysts have recently commented on KYMR shares. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. BMO Capital Markets initiated coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective for the company. UBS Group lowered their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. BTIG Research began coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target on the stock. Finally, Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th.

Kymera Therapeutics Trading Up 1.6 %

Shares of KYMR opened at $40.89 on Friday. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -17.47 and a beta of 2.16. The business’s fifty day simple moving average is $44.96 and its two-hundred day simple moving average is $43.59. Kymera Therapeutics has a 12 month low of $22.35 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.90) earnings per share. As a group, research analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its position in shares of Kymera Therapeutics by 19.3% during the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company’s stock worth $4,663,000 after acquiring an additional 25,317 shares during the period. Rhumbline Advisers grew its stake in Kymera Therapeutics by 12.4% in the second quarter. Rhumbline Advisers now owns 64,535 shares of the company’s stock worth $1,926,000 after purchasing an additional 7,143 shares in the last quarter. Arizona State Retirement System increased its holdings in Kymera Therapeutics by 15.6% during the 2nd quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock worth $383,000 after purchasing an additional 1,730 shares during the period. Quest Partners LLC raised its position in Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after purchasing an additional 4,865 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Kymera Therapeutics by 2.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 405,870 shares of the company’s stock worth $12,115,000 after buying an additional 10,731 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.